Cao Jian-Zhou, Pan Jin-Feng, Ng Derry Mingyao, Ying Meng-Qi, Jiang Jun-Hui, Ma Qi
Medical School, Ningbo University, Ningbo, Zhejiang, 315211, People's Republic of China.
Comprehensive Urogenital Cancer Center, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, 315010, People's Republic of China.
Onco Targets Ther. 2021 Apr 21;14:2797-2803. doi: 10.2147/OTT.S297603. eCollection 2021.
Prostate cancer (PCa) is one of the most common types of malignancy, most patients with PCa will eventually progress to metastatic castration-resistant prostate cancer (mCRPC), which has a poor prognosis. Since 2004, chemotherapy has been approved by the FDA as the first-line treatment for mCRPC, and docetaxel-based regimens have been shown to improve both the patients' symptoms and overall survival (OS). 10 cycles of docetaxel therapy are usually given to patients with mCPRC, but there is still no consensus on the optimal number of treatment cycles. Here, we present three cases of mCRPC patients that received maintenance long-term multiple-cycles docetaxel treatment. We believe that this new treatment strategy may benefit carefully selected mCRPC patients and provide several key advantages such as maximum exposure to drugs, improvements in drug efficacy, and reduce the risk of developing drug resistance.
前列腺癌（PCa）是最常见的恶性肿瘤类型之一，大多数前列腺癌患者最终会进展为转移性去势抵抗性前列腺癌（mCRPC），其预后较差。自2004年以来，化疗已被美国食品药品监督管理局（FDA）批准为mCRPC的一线治疗方法，基于多西他赛的治疗方案已被证明可改善患者症状和总生存期（OS）。通常会给mCRPC患者进行10个周期的多西他赛治疗，但对于最佳治疗周期数仍未达成共识。在此，我们介绍3例接受多西他赛长期多周期维持治疗的mCRPC患者。我们认为，这种新的治疗策略可能会使经过精心挑选的mCRPC患者受益，并具有几个关键优势，如最大程度地接触药物、提高药物疗效以及降低产生耐药性风险。
